XTX Topco Ltd Purchases New Stake in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

XTX Topco Ltd bought a new stake in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 111,245 shares of the company’s stock, valued at approximately $65,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in XFOR. Bain Capital Life Sciences Investors LLC increased its stake in shares of X4 Pharmaceuticals by 6.0% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 16,915,784 shares of the company’s stock valued at $14,184,000 after purchasing an additional 955,196 shares during the last quarter. Kingdon Capital Management L.L.C. boosted its stake in X4 Pharmaceuticals by 76.0% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company’s stock valued at $2,913,000 after buying an additional 1,500,000 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of X4 Pharmaceuticals by 14.6% in the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after acquiring an additional 23,831 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of X4 Pharmaceuticals by 39.7% in the second quarter. Bank of New York Mellon Corp now owns 469,372 shares of the company’s stock worth $272,000 after acquiring an additional 133,398 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in X4 Pharmaceuticals by 46.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock worth $55,000 after purchasing an additional 12,514 shares in the last quarter. 72.03% of the stock is currently owned by institutional investors and hedge funds.

X4 Pharmaceuticals Stock Performance

Shares of XFOR stock opened at $0.61 on Thursday. The business’s 50-day moving average price is $0.70 and its 200-day moving average price is $0.91. X4 Pharmaceuticals, Inc. has a 12 month low of $0.53 and a 12 month high of $1.60. The company has a current ratio of 6.07, a quick ratio of 6.04 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $102.34 million, a price-to-earnings ratio of -0.87 and a beta of 0.36.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.03). The firm had revenue of $0.56 million for the quarter, compared to the consensus estimate of $52.98 million. During the same quarter in the previous year, the business posted ($0.33) EPS. Equities research analysts forecast that X4 Pharmaceuticals, Inc. will post -0.65 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of X4 Pharmaceuticals in a research report on Friday, June 28th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.